logo
Pharmaniaga shares soar past 45pc, volume hits two-year high

Pharmaniaga shares soar past 45pc, volume hits two-year high

KUALA LUMPUR: Shares of Pharmaniaga Bhd soared more than 45 per cent in active trade, as buying momentum lifted trading volume to levels not seen in over two years.
At 11.54am, the stock was up six sen or 38.71 per cent at 21.5 sen, with 51 million shares changing hands, its busiest day since April 20, 2023. It was the second most actively traded counter at the time.
The stock opened 9.68 per cent higher at 17 sen and rose as much as 22.5 sen, up 45.16 per cent from its previous close of 15.5 sen.
There have been no fresh corporate announcements aside from the renounceable rights issue of up to 3.52 billion shares announced earlier this month.
On July 1, the counter went ex-rights, triggering a technical price adjustment from 23.5 sen on June 30 to 16 sen.
Until today's rally, the stock had been trading between 14 sen and 16.5 sen. At 22 sen, it is now edging back toward its pre-rights issue level above 20 sen.
Pharmaniaga, once weighed down by a RM552.3 million impairment from unsold Covid-19 vaccines, slipped into Practice Note 17 (PN17) status in February 2023.
But the company has since returned to profitability in the financial year ended Dec 31, 2024 (FY24) and expects to stay in the black in FY25.
The group is eyeing revenue of RM4 billion this year, up from RM3.8 billion in FY24, a level it last crossed in FY21.
Its managing director Zulkifli Jafar has said the company aims to exit PN17 status by the end of this year or early 2026.
Pharmaniaga is majority-owned by Boustead Holdings Bhd, which in turn is controlled by Lembaga Tabung Angkatan Tentera (LTAT).
According to the latest annual report, LTAT holds a direct 44.47 per cent stake in the company.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Pharmaniaga completes regularisation plan, set to exit PN17 by Q1 2026
Pharmaniaga completes regularisation plan, set to exit PN17 by Q1 2026

Malay Mail

timean hour ago

  • Malay Mail

Pharmaniaga completes regularisation plan, set to exit PN17 by Q1 2026

KUALA LUMPUR, Aug 7 — Pharmaniaga Bhd has completed its Practice Note 17 (PN17) regularisation plan following the completion of its capital reduction exercise through the cancellation of RM520 million in issued share capital. In a statement yesterday, the pharmaceutical company said the step firmly sets the group on course to exit the PN17 status latest by the first quarter (1Q) of 2026. 'The capital reduction exercise, which involved the cancellation of RM520 million in issued share capital, was completed after confirmation was received today from the Registrar of Companies that all statutory requirements have been fulfilled. 'Following the completion of this exercise, the issued share capital of the group is RM249.62 million, comprising 6.55 billion shares,' it said. Pharmaniaga fell into PN17 status in February 2023, dragged by its RM552.3 million provision for 'slow-moving inventories' of Covid-19 vaccines. At the close of trading yesterday, the counter finished unchanged at 18.5 sen, with 28.69 million shares changing hands. — Bernama

Pharmaniaga completes regularisation plan, set to exit PN17 by 2026
Pharmaniaga completes regularisation plan, set to exit PN17 by 2026

New Straits Times

time2 hours ago

  • New Straits Times

Pharmaniaga completes regularisation plan, set to exit PN17 by 2026

KUALA LUMPUR: Pharmaniaga Bhd has completed its Practice Note 17 (PN17) regularisation plan following the completion of its capital reduction exercise through the cancellation of RM520 million in issued share capital. In a statement today, the pharmaceutical company said the step firmly sets the group on course to exit the PN17 status latest by the first quarter (1Q) of 2026. "The capital reduction exercise, which involved the cancellation of RM520 million in issued share capital, was completed after confirmation was received today from the Registrar of Companies that all statutory requirements have been fulfilled. "Following the completion of this exercise, the issued share capital of the group is RM249.62 million, comprising 6.55 billion shares," it said. Pharmaniaga fell into PN17 status in February 2023, dragged by its RM552.3 million provision for "slow-moving inventories" of COVID-19 vaccines. At the close of trading today, the counter finished unchanged at 18.5 sen, with 28.69 million shares changing hands.

Klang Valley to remain mainstay of industrial hubs
Klang Valley to remain mainstay of industrial hubs

The Star

time6 hours ago

  • The Star

Klang Valley to remain mainstay of industrial hubs

Knight Frank Malaysia said that between 2020 and 2024, annual industrial transaction values in the Klang Valley and Johor Baru grew by an 18% and 40% four-year compounded annual growth rate, respectively. PETALING JAYA: Klang Valley will likely remain the largest industrial hub in the country on the back of its relatively more mature industrial parks, infrastructure and strategic access to ports, according to Kenanga Research. Specifically on Johor, the research house gathered that its industrial and data centre boom commenced with the launch of YTL Green Data Centre Park in Kulai in August 2022. This kick-started interests by large multinationals in the state, further fuelling its investments into that space, it noted. The research house said with the officiation of Johor's Forest City Special Financial Zone in September 2024 and Johor-Singapore Special Economic Zone in January 2025, in addition to the increase in cross-border activities with Singapore stemming from the upcoming launch of the Rapid Transit System link, it believes that activities and investments into the state could remain buoyant in the near-to-medium term. According to property consultancy company Knight Frank Malaysia, between 2020 and 2024, annual industrial transaction values in Klang Valley and Johor Baru (including Kulai) grew by an 18% and 40% four-year compounded annual growth rate, respectively. While this could be attributed to pent-up demand coming out of the Covid-19 pandemic, it ties in with the increase of capital investments injected into the mentioned regions, Kenanga Research said. Kenanga Research believes Penang remains a hot spot for industrial activity, mostly dominated by the technology and semiconductor sectors. The brokerage recently co-organised a real estate event with Knight Frank on the property consultancy's exclusive launch of its half-yearly real estate highlights for the first half of 2025. Focusing on high-rise residential trends, Knight Frank highlighted that transaction volumes and values in Kuala Lumpur had picked up mostly in 2022, coming out of the pandemic. Knight Frank found it worth noting as well that the growth of average transaction values had outpaced volumes, reflecting a higher appetite by homebuyers for higher-priced homes. From Kenanga Research's checks among property developers and mortgage lenders, the pick-up in transaction volumes in 2022 could have been made up by more affordable offerings (RM300,000 to RM500,000) which led market launches at that time, owing to development being stalled by the movement control orders between 2020 and 2021. On the data centre front, there was a surge in data centre investments post-Covid-19, with total investment reaching RM160bil in 2024, more than triple the amount in 2023. However, the sector is now entering a more mature execution phase of announced plans, Knight Frank noted. In the first half of 2025, digital investments totalled RM42.6bil versus RM66.2bil in the similar period last year, with over 70% allocated to data centres and cloud infrastructure. While Johor continues to lead in data centre development, Klang Valley has also seen healthy activity.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store